• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cinclus Pharma

12.22 SEK

+1.66 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.66 %
+3.74 %
-28.37 %
-36.55 %
-26.74 %
-24.10 %
-
-
-62.52 %

Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
579.13M SEK
Turnover
1.31M SEK
Revenue
57.47M
EBIT %
-347.24 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
19.8
2026

Interim report Q2'26

11.11
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/3/2026, 6:00 AM

Cinclus Pharma Achieves Key Phase III Milestone: Last Patient Screened in HEEALING1 Study

Cinclus Pharma
Regulatory press release5/21/2026, 4:05 PM

Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) on 21 May 2026

Cinclus Pharma
Press release5/13/2026, 12:46 PM

Redeye: Cinclus Pharma (Q1 Review): Strengthened finances enables a seamless transition

Cinclus Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Cinclus Pharma, Audiocast, Q1'26
Webcast5/13/2026, 8:00 AM

Cinclus Pharma, Audiocast, Q1'26

Cinclus Pharma
Regulatory press release5/13/2026, 6:00 AM

Interim report January-March 2026 - Phase III study approaching full enrollment

Cinclus Pharma
Press release4/29/2026, 6:00 AM

Invitation to presentation of Cinclus Pharma’s first quarter report 2026

Cinclus Pharma
Regulatory press release4/16/2026, 10:00 AM

Cinclus Pharma publishes its Annual Report for 2025

Cinclus Pharma
Regulatory press release4/16/2026, 7:30 AM

Notice of Annual General Meeting in Cinclus Pharma Holding AB (publ)

Cinclus Pharma
Press release3/31/2026, 6:00 AM

Cinclus Pharma to participate in upcoming investor conferences

Cinclus Pharma
Regulatory press release3/13/2026, 7:30 AM

Cinclus Pharma Enters into EUR 28 Million Financing Agreement

Cinclus Pharma
Press release2/23/2026, 7:00 AM

Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive for the Company’s Phase III Program

Cinclus Pharma
Press release2/18/2026, 11:31 AM

Redeye: Cinclus Pharma (Q4 Review): Phase III advancing on time

Cinclus Pharma
Cinclus Pharma, Audiocast, Q4'25
Webcast2/18/2026, 9:00 AM

Cinclus Pharma, Audiocast, Q4'25

Cinclus Pharma
Regulatory press release2/18/2026, 7:00 AM

Year-end report – Advancing toward Phase III readout

Cinclus Pharma
Press release2/13/2026, 7:00 AM

Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA

Cinclus Pharma
Press release2/10/2026, 7:00 AM

Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate

Cinclus Pharma
Press release2/4/2026, 7:00 AM

Invitation to presentation of Cinclus Pharma’s fourth quarter report 2025

Cinclus Pharma
Regulatory press release1/19/2026, 4:10 PM

Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026

Cinclus Pharma
Regulatory press release12/8/2025, 7:00 AM

Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing and is set to launch in China in 2026

Cinclus Pharma
Regulatory press release12/8/2025, 6:30 AM

Cinclus Pharma recruits Magnus Christensen as new CFO

Cinclus Pharma